Lilly Rejected by U.S. Supreme Court in Gemzar Patent Case
This article is for subscribers only.
The U.S. Supreme Court refused to consider Eli Lilly & Co.’s bid to re-establish the drugmaker’s exclusive right to sell the cancer medicine Gemzar.
The justices today left intact a federal appeals court decision invalidating a patent that would have protected Gemzar from generic competition in the U.S. until May 2013.